Physician profile
Jonathan M Simhaee
NPI 1215160114
$3,905.53
in general payments reported to CMS, 2019-2025
26 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $511 · 2021: $647 · 2022: $714 · 2023: $470 · 2024: $392 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,021.98 | 2023-2025 | |
| Abbvie INC. | $446.94 | 2021-2023 | Qulipta |
| Biohaven Pharmaceutical Holding Company LTD. | $397.84 | 2022 | |
| Si-Bone, INC. | $325.90 | 2019-2023 | |
| Stryker Corporation | $292.78 | 2019-2023 | Vitoss |
| Biohaven Pharmaceuticals, INC. | $258.18 | 2021 | |
| Nevro Corp. | $247.91 | 2019-2024 | Senza |
| Abbott Laboratories | $183.07 | 2019-2020 | |
| Boston Scientific Corporation | $130.89 | 2020-2022 | |
| Horizon Therapeutics Plc | $121.91 | 2019-2022 | |
| Depuy Synthes Sales INC. | $89.34 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $72.37 | 2025 | |
| Saluda Medical Americas, INC. | $47.21 | 2025 | Evoke |
| Fidia Pharma USA INC. | $46.43 | 2023-2024 | Hymovis, Triluron, Hyalgan |
| Surgalign Spine Technologies, INC. | $41.45 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.30 | 2023 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $20.31 | 2020 | |
| Epimed International, INC | $18.79 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $17.33 | 2021 | |
| Arteriocyte Medical Systems, INC. | $16.43 | 2021 | |
| Zyla Life Sciences, INC. | $14.70 | 2019 | |
| Orthofix Medical, INC. | $13.79 | 2021 | |
| Royal Biologics, INC. | $13.73 | 2020 | |
| Avanos Medical | $12.15 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.15 | 2020 | |
| Medtronic USA, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Simhaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.